GHK-Cu vs TB-500
Reviewed by the BestHealingPeptides Editorial Team ·
GHK-Cu and TB-500 are sometimes grouped together as 'tissue-repair peptides', but the two operate at very different scales — GHK-Cu primarily as a transcriptional modulator of dermal fibroblasts, TB-500 primarily as a cell-migration peptide.
GHK-Cu
A naturally occurring copper-binding tripeptide (Gly-His-Lys) complexed with Cu(II). Extensively studied in dermatology for wound healing, collagen synthesis, antioxidant defence, and hair-follicle stimulation.
TB-500
A synthetic peptide commonly described as a fragment of thymosin beta-4 incorporating the actin-binding 'LKKTETQ' motif. Studied for soft-tissue repair, wound healing, and cardiac tissue regeneration in animal models.
| Aspect | GHK-Cu | TB-500 |
|---|---|---|
| Lead mechanism | Cu(II) delivery → fibroblast transcriptional programme (collagen, elastin, antioxidant genes) | Actin sequestration → directed cell migration |
| Standard route | Topical (cosmetic + research) | Injectable (lyophilised, BAC water) |
| Typical concentrations | 1–10 nM in vitro; 0.05–0.5% topical | Reconstituted to research-specified concentration |
| Dermal evidence | Substantial — gene-expression and topical wound studies | Mostly extrapolated from full-length Tβ4 |
| UK regulatory | Legal cosmetic ingredient; not licensed as medicine | Not licensed; WADA S2 |
| Key formulation gotcha | Avoid co-formulation with reducing agents (vitamin C disrupts Cu²⁺) | Plastic adsorption; use low-binding labware |
Mechanism
GHK-Cu acts as a copper-delivery vehicle and broad transcriptional modulator, with strong effects on collagen, elastin, and antioxidant gene expression in fibroblasts. TB-500 is positioned as an actin-binding fragment that promotes cell migration and angiogenesis.
Dermal evidence
GHK-Cu has by far the larger dermatological evidence base, including topical wound-healing studies, cosmetic clinical work, and gene-expression analyses. TB-500's dermal evidence is mostly extrapolated from full-length thymosin beta-4.
Formulation and route
GHK-Cu is commonly used topically in research formulations (nM concentrations in vitro, 0.05–0.5% in topical preparations). TB-500 is typically used as an injectable lyophilised peptide reconstituted with bacteriostatic water.
Regulatory
GHK-Cu is widely used as a legal cosmetic ingredient in the UK; neither peptide is licensed for therapeutic use. TB-500 sits under WADA S2; GHK-Cu is not specifically listed.
Verdict
For dermal research, GHK-Cu has the stronger and longer-standing evidence base. TB-500 remains relevant to research on injectable soft-tissue repair, where its actin-binding effects are most plausible.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.